＜文献＞

1. Abelev GI, Perova S, Khramkova N, Postinikova Z, Irlin Y, Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation. 1: 174-180, 1963.

2. Alpert ME, Uriel J, de Nechaud B: Alpha1-fetoglobulin in the diagnosis of human hepatoma. N Engl J Med 278: 984-986, 1968.

3. O'Conor GI, Tatarinov YS, Abelev GI, Uriel J, A collaborative study for the evaluation of a serologic test for primary liver cancer. Cancer 25: 1091-1098, 1970.

4. Nishi S, Hirai H. Radioimmunoassay of alpha-fetoprotein in hepatoma, other liver diseases, and pregnancy. Gann Monogr 14:79-817, 1973.

5. Masopust J, Kithier K, Radl J, Koutecky J, Kotal L, Occurrence of fetoprotein in patients with neoplasma and nonneoplastic diseases. Int J Cancer 3: 364-373, 1968.

6. Karvountzis GG, Redeker AG. Relation of alpha-fetoprotein in acute hepatitis to severity and prognosis. Intern Med 80: 156-160, 1974.

7. Gitlin D, Boesman M, Serum alpha-fetoprotein, albumin, and γG-globulin in the human conceptus. J Clin Invest 45: 1826-1838, 1966.

8. Gitlin D, Boesman M. Sites of serum alpha-fetoprotein synthesis in the human and in the rat. J Clin Invest. 46: 1010-6, 1967.

9. 第 19 回全国原発性肝癌追跡調査報告，日本肝癌研究会，肝癌追跡調査委員会，メディア・プランニング，2014.

10. **Aoyagi Y**, Ikenaka T, and Ichida F. Comparative chemical structures of human alpha-fetoprotein from fetal serum and from ascites fluid of a patient with hepatoma. Cancer Res., 37: 3663-3667, 1977.

11. **Aoyagi Y**, Ikenaka T, Ichida F, Copper(II)-binding ability of human alpha-fetoprotein. Cancer Res, 38: 3483-3486, 1978.

12. **Aoyagi Y**, Ikenaka T, Ichida F, alpha-Fetoprotein as a carrier protein in plasma and its bilirubin-binding ability. Cancer Res 39: 3571-3574, 1979.

13. **Aoyagi Y**, Takahashi T, Odani S, Ogata K, Ono T, Ichida F, Inhibitory effect of alpha-fetoprotein on protein synthesis in a reticulocyte lysate cell-free system. J Biol Chem 257: 9566-9569, 1982.

14. Morinaga, T., Sakai, M., Wegmann, T.G. & Tamaoki, T. Primary structures of human alpha-fetoprotein and its mRNA. Proc. Natl. Acad. Sci. 80: 4604-4608, 1983.

15. Gibbs, P.E.M., Zielinski, R., Boyd C, Dugaiczyk, Structure, polymorphism, and novel repeated DNA elements revealed by a complete sequence of the human alpha-fetoprotein gene. Biochemistry. 26: 1332-43, 1987.

16. Urano, Y., Sakai, M., Watanabe, K, Tamaoki, T. Tandem arrangement of the

albumin and alpha-fetoprotein genes in the human genome. Gene, 32: 255-61, 1984.
17. **Aoyagi Y**, Suzuki Y, Isemura M, Soga K, Ozaki T. Ichida T, Inoue K, Sasaki H, and Ichida, F. Differential reactivity of alpha-fetoprotein with lectins and evaluation of its usefulness in the diagnosis of hepatocellular carcinoma. Gann, 75: 809-815, 1984.
18. **Aoyagi Y**, Isemura M, Suzuki Y, et al. Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma. Lancet, ii: 1353-1354, 1985.
19. **Aoyagi Y**, Suzuki Y, Isemura M, Nomoto M, Sekine C, Igarashi K, and Ichida F. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer, 61: 769-774, 1988.
20. **Aoyagi Y**, Suzuki Y, Igarashi K, Saitoh A, Isemura M, Oguro M, Yokota T, Nomoto M. and Asakura H. The usefulness of the simultaneous determinations of glucosaminylation and fucosylation indices of alpha-fetoprotein in the differential diagnosis of neoplastic diseases of the liver. Cancer, 67: 2390-2394, 1991.
21. **Aoyagi Y**, Suzuki Y, Igarashi K, Yokota T, Mori S, Suda T, Isemura M. and Asakura H. Highly enhanced fucosylation of alpha-fetoprotein in patients with germ cell tumor. Cancer, 72: 615-618, 1993.
22. **Aoyagi Y**, Isemura M, Yosizawa Z, Suzuki Y, Sekine C, Ono T. and Ichida F. Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma. Biochim Biophys Acta, 830: 217-223, 1985.
23. **Aoyagi Y**, Suzuki Y, Igarashi K, Saitoh A, Oguro M, Yokota T, Mori S, Suda T, Isemura M. and Asakura H. Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans. Brit J Cancer, 67: 486-492, 1993.
24. Taketa K, Ichikawa E, Taga H, Hirai H: Antiboby-affinity blotting, a sensitive technique for the detection of alpha-fetoprotein separated by lectin affinity electrophoresis in agarose gels. Electrophoresis, 6: 492-497, 1985.
25. Taketa K, Endo Y, Sekiya C, Tanikawa K, Koji T, Taga H, Satomura S, Matsuura S, Kawai T, Hirai H. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res. 53: 5419-23, 1993.
26. **Aoyagi Y**. Molecular discrimination between alpha-fetoprotein from patients with hepatocellular carcinoma and nonneoplastic liver diseases by their carbohydrate structures. Review Article. Int. J. Oncology, 4: 369-383, 1994.
27. **Aoyagi Y**. Carbohydrate-based measurement on alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma. Mini-Review. Glycoconjugate Journal, 12: 194-199, 1995.

28. **Aoyagi Y**, Isemura M, Suzuki Y, Sekine C, Soga K, Ozaki K. and Ichida F. Change in fucosylation of alpha-fetoprotein on malignant transformation of liver cells. Lancet, i: 210, 1986.
29. **Aoyagi Y**, Saitoh A, Suzuki Y, Igarashi K, Oguro M, Yokota T, Mori S, Suda T, Isemura M, and Asakura, H. Fucosylation index of alpha-fetoprotein, a possible aid in early recognition of hepatocellular carcinoma in patients with cirrhosis. Hepatology, 17: 50-52, 1993.
30. Sekine C, **Aoyagi Y**, Suzuki Y, Ichida F. The reactivity of alpha-1-antitrypsin with Lens culinaris agglutinin and its usefulness in the diagnosis of neoplastic diseases of the liver. Brit J Cancer, 56: 371-375, 1987.
31. Saitoh A, **Aoyagi Y**, and Asakura H. Structural analysis on the sugar chains of alpha-1-antitrypsin: Presence of fucosylated biantennary glycan in hepatocellular carcinoma. Arch Biochem Biophys, 303: 281-287, 1993.
32. Suzuki Y, **Aoyagi Y**, Mori S, Suda T, Yanagi M, and Asakura H. Microheterogeneity of serum transferrin in the diagnosis of hepatocellular carcinoma. J Gastroenterol Hepatol, 11: 358-365, 1996.
33. Naitoh A, **Aoyagi Y**, Asakura H. Highly enhanced fucosylation of serum glycoproteins in patients with hepatocellular carcinoma, correlation of the fucosylations between alpha-fetoprotein, alpha-1-antitrypsin and transferrin. J Gastroenterol Hepatol. 14: 432-441, 1999.
34. **Aoyagi Y**, Isokawa O, Suda T, Watanabe M, Suzuki Y, Asakura H, The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. Cancer, 83: 2076-2082, 1998.
35. 厚生労働科学研究費補助金(肝炎等克服緊急対策研究事業)総括研究報告書（平成17-19 年度）AFP-L3 分画および血流中癌細胞テロメラーゼを指標とした肝細胞癌のサーベイランスの有用性に関する研究，主任研究者，**青柳 豊**，分担研究者恩地森一，田中栄司，高木均.
36. Yamagata Y, Shimizu K, Nakamura K, Henmi F, Satomura S, Matsuura S, Tanaka M. Simultaneous determination of percentage of *Lens culinaris* agglutinin-reactive alpha-fetoprotein and alpha-fetoprotein concentration using the LiBASys clinical auto-analyzer. Clin Chim Acta. 327:59-67, 2003.
37. Suzuki Y, **Aoyagi Y**, Muramatsu M, Isemura M. and Ichida F. Close topographical relationship in alpha-foetoprotein(AFP) between a lens culinaris binding glycan and the epitope recognized by AFP-reactive monoclonal antibody, 18H4. Brit J Cancer, 55: 147-152, 1987.
38. Suzuki Y, **Aoyagi Y**, Muramatsu M, Igarashi K, Saitoh A, Oguro M, Isemura M,

and Asakura H. A lectin-based monoclonal enzyme immunoassay to distinguish fucosylated and non-fucosylated alpha-fetoprotein molecular variants. Ann Clin Biochem, 27: 121-128, 1990.

39. Tamura Y, Yamagiwa S, Aoki Y, Kurita S, Suda T, Ohkoshi S, Nomoto M, **Aoyagi Y**. Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci. 54: 2530-7, 2009.

40. Tamura Y, Igarashi M, Suda T, Wakai T, Shirai Y, Umemura T, Tanaka T, Kakizaki S, Takagi H, Hiasa Y, Onji M, **Aoyagi Y**. Fucosylated fraction of alpha-fetoprotein as a predictor of prognosis in patients with hepatocellular carcinoma after curative treatment. Dig Dis Sci. 55: 2095-101, 2010.

41. Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, **Aoyagi Y**. Clinical Advantage of Highly Sensitive On-Chip Immunoassay for Fucosylated Fraction of Alpha-Fetoprotein in Patients with Hepatocellular Carcinoma. Dig Dis Sci. 55: 3576-83, 2010.

42. **Aoyagi Y**, Tamura Y, Suda T, EDITORIAL, History and recent progress in evaluation of the fucosylated alpha-fetoprotein fraction, J Gastroenterol Hepatol, 26: 615-6. 2011.

43. Tamura Y, Suda T, Arii S, Sata M, Moriyasu F, Imamura H, Kawasaki S, Izumi N, Takayama T, Kokudo N, Yamamoto M, Iijima H, **Aoyagi Y**. Value of Highly Sensitive Fucosylated Fraction of Alpha-Fetoprotein for Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment. Dig Dis Sci. 58: 2406-12, 2013.

44. **Aoyagi Y**, Mita Y, Suda T, Kawai K, Kuroiwa T, Igarashi M, Kobayashi M, Waguri N, Asakura H. The fucosylation index of serum alpha-fetoprotein as useful prognostic factor in patients with hepatocellular carcinoma in special reference to chronological changes. Hepatolgy Res. 23: 287-295, 2002.

45. Igarashi H, **Aoyagi Y**, Suda T, Mita Y, Kawai H, Studies on the correlation among the fucosylation index, concentration of alpah-fetoprotein and des-gamma-carboxy prothrombin as prognostic indicators in hepatocellular carcinoma. Hepatolgy Res. 27: 280-288, 2003.

46. Kobayashi M, Kuroiwa T, Suda T, Tamura Y, Kawai H, Igarashi M, Fukuhara Y, **Aoyagi Y**. Fucosylated fraction of alpha-fetoprotein, L3, as a useful prognostic factor in patients with hepatocellular carcinoma with special reference to the low concentration of serum alpha-fetoprotein. Hepatol Res. 37: 914-22, 2007.

47. Mita Y, **Aoyagi Y**, Suda T, Asakura H, Plasma fucosyltransferase activity in patients with hepatocellular carcinoma, with special reference to correlation with

fucosylated species of alpha-fetoprotein. J Hepatology, 32: 946-954, 2000.

48. Mori S, **Aoyagi Y**, Yanagi M, Suzuki Y, Asakura H. N-acetylglucosaminyltransferase III activities in hepatocellular carcinoma. J Gastroenterol Hepatol. 13: 610-619, 1998.
49. Yanagi M, **Aoyagi Y**, Suda T, Mita Y, Asakura H. N-acetylglucosaminyltransferase V as a possible aid for the evaluation of tumor invasiveness in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 16: 1282-1289, 2001.
50. **Aoyagi Y**, Mori S, Naitoh A, Yanagi M, Suzuki Y, Suda T, Isokawa O, Igarashi, H, Takahashi T, Isemura M, and Asakura H. Alpha-fetoprotein producing renal cell carcinoma with the increased activity of N-acetylglucosaminyltransferase III. Nephron, 74: 409-414, 1996.